LARIMAR THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $154.2M | $73.3M | $27.7M | $24.3M | $38.4M | $31.4M | $20.8M |
| SG&A Expense | — | $18.3M | $17.6M | $14.1M | $12.3M | $12.1M | $11.4M | $2.4M |
| Operating Income | — | $-172.5M | $-90.9M | $-41.8M | $-36.5M | $-50.5M | $-42.8M | $-23.2M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | $1.8M |
| Pretax Income | — | $-165.7M | $-80.6M | $-36.9M | $-35.4M | $-50.6M | $-42.5M | $-23.2M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-165.7M | $-80.6M | $-36.9M | $-35.4M | $-50.6M | $-42.5M | $-23.1M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | $-1.32 | $-0.84 | $-1.37 | $-2.95 | $-3.57 | $-3.80 |
| EPS (Diluted) | — | — | $-1.32 | $-0.84 | $-1.37 | $-2.95 | $-3.57 | $-3.80 |
| Shares Outstanding (Basic) | 103.9M | 83.1M | 61.3M | 43.9M | 25.8M | 17.2M | 11.9M | 6.1M |
| Shares Outstanding (Diluted) | 103.9M | 83.1M | 61.3M | 43.9M | 25.8M | 17.2M | 11.9M | 6.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |